Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.vaccine.2010.02.087
Title: Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial
Authors: Russell, F.M.
Carapetis, J.R.
Balloch, A.
Licciardi, P.V.
Jenney, A.W.J.
Tikoduadua, L.
Waqatakirewa, L.
Pryor, J.
Nelson, J.
Byrnes, G.B.
Cheung, Y.B. 
Tang, M.L.K.
Mulholland, E.K.
Keywords: Hyporesponsiveness
Immunogenicity
Pneumococcal vaccines
Issue Date: 26-Apr-2010
Citation: Russell, F.M., Carapetis, J.R., Balloch, A., Licciardi, P.V., Jenney, A.W.J., Tikoduadua, L., Waqatakirewa, L., Pryor, J., Nelson, J., Byrnes, G.B., Cheung, Y.B., Tang, M.L.K., Mulholland, E.K. (2010-04-26). Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 28 (19) : 3341-3349. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2010.02.087
Abstract: Background: To evaluate the immunological impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months, for children who have received zero to three infant doses of seven-valent pneumococcal conjugate vaccine (PCV), on responses to a subsequent exposure to a small dose of 23vPPS (mPPS). Methods: Five hundred and fifty-two Fijian infants were stratified by ethnicity and randomized into eight groups to receive zero, one, two, or three PCV doses at 14 weeks, six and 14 weeks, or six, ten, and 14 weeks. Within each group, half received 23vPPS at 12 months and all received mPPS at 17 months. Sera were taken prior and one month post-mPPS. Findings: By 17 months, geometric mean antibody concentrations (GMC) to all 23 serotypes in 23vPPS were significantly higher in children who had received 23vPPS at 12 months compared to those who had not. Post-mPPS, children who had not received the 12 month 23vPPS had a significantly higher GMC for all PCV serotypes compared with those who had (each p < 0.02). For the non-PCV serotypes, children who had not received the 12 month 23vPPS had significantly higher GMC for six of 16 non-PCV serotypes (7F, 9N, 12F, 19A, 22F, 33F) than those who did (each p < 0.02). After adjusting for the pre-mPPS level, exposure to 23vPPS was associated with a lower response to mPPS for all serotypes (each p < 0.001). Interpretation: Despite higher antibody concentrations at 17 months in children who had received 23vPPS at 12 months, the response to a re-challenge was poor for all 23 serotypes compared to children who had not received the 12 month 23vPPS. © 2010 Elsevier Ltd.
Source Title: Vaccine
URI: http://scholarbank.nus.edu.sg/handle/10635/110116
ISSN: 0264410X
DOI: 10.1016/j.vaccine.2010.02.087
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

62
checked on Nov 21, 2022

WEB OF SCIENCETM
Citations

58
checked on Nov 14, 2022

Page view(s)

129
checked on Nov 24, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.